The Effect of Comorbidities on the Choice of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia
Makaleler > Tam Makale · 2022
Yazarlar: Güray SAYDAM, Ridvan Ali, Ahmet Muzaffer Demir, Ahmet Emre Eskazan, Birol Guvenc, Ibrahim Celalettin Haznedaroglu, Mehmet Ali Ozcan, Ozan Salim, Mehmet Sonmez, Ayse Tulin Tuglular, Mehmet Turgut, Ali Unal, Birkan Aver, Sirac Bozkurt, Begum Ozdengulsun, Osman Ilhan
International Journal of Hematologic Oncology, Uluslararası, 2022, cilt 11, ss IJH38-IJH38
Özet
Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of TKIs. This review article examines the most up-to-date data and provides practical recommendations for clinical approaches. Nilotinib and ponatinib should be avoided in patients with cardiovascular risk factors, dasatinib in patients with lung damage and bosutinib and nilotinib in patients with liver disease. Considering that certain comorbidities predispose some patients to developing severe adverse events when receiving TKIs, the first- and second-line treatment of chronic myeloid leukemia should be tailored to each patient's individual condition.